AR106533A1 - COMBINATION OF THERAPIES FOR HEMO DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS - Google Patents

COMBINATION OF THERAPIES FOR HEMO DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS

Info

Publication number
AR106533A1
AR106533A1 ARP160103317A ARP160103317A AR106533A1 AR 106533 A1 AR106533 A1 AR 106533A1 AR P160103317 A ARP160103317 A AR P160103317A AR P160103317 A ARP160103317 A AR P160103317A AR 106533 A1 AR106533 A1 AR 106533A1
Authority
AR
Argentina
Prior art keywords
antibodies
inhibitors
diseases
therapies
survivine
Prior art date
Application number
ARP160103317A
Other languages
Spanish (es)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR106533A1 publication Critical patent/AR106533A1/en

Links

Abstract

Terapias de combinación para enfermedades malignas heme con anticuerpos anti-CD38 e inhibidores de survivina.Combination therapies for malignant diseases heme with anti-CD38 antibodies and survivin inhibitors.

ARP160103317A 2016-04-06 2016-10-31 COMBINATION OF THERAPIES FOR HEMO DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS AR106533A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319036P 2016-04-06 2016-04-06

Publications (1)

Publication Number Publication Date
AR106533A1 true AR106533A1 (en) 2018-01-24

Family

ID=61021866

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103317A AR106533A1 (en) 2016-04-06 2016-10-31 COMBINATION OF THERAPIES FOR HEMO DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS

Country Status (2)

Country Link
AR (1) AR106533A1 (en)
TW (1) TWI724046B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064182B (en) * 2014-09-09 2021-09-03 詹森生物科技公司 Combination therapy with anti-CD 38 antibodies

Also Published As

Publication number Publication date
TWI724046B (en) 2021-04-11
TW201735946A (en) 2017-10-16

Similar Documents

Publication Publication Date Title
DOP2018000181A (en) COMBINATION THERAPIES FOR HEMATOLOGICAL MALIGNAL DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS
CL2019000061A1 (en) Antibody for anti-claudin 18a2 and its use.
ZA202107931B (en) Anti-tau antibodies and methods of use
ECSP17083788A (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGIC MALIGNANT DISEASES
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EA201790984A1 (en) ANTI-CD79B ANTIBODIES AND METHODS OF THEIR APPLICATION
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
BR112019012342A2 (en) il-11 antibodies
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
CR20190271A (en) Anti-tau antibodies and methods of use
CR20170131A (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
BR112016019871A2 (en) anti-cd38 antibodies for the treatment of acute lymphoblastic leukemia
CR20160362A (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
BR112016007891A2 (en) use of cbp / ep300 bromodomain inhibitors for cancer immunotherapy
BR112017013568A2 (en) fused bicyclic compounds for treating diseases
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
ES2721935T3 (en) Anti-BAG3 antibodies for therapeutic use
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
CL2016000999A1 (en) Specific anti-cd38 antibodies to treat human cancers
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.
AR106533A1 (en) COMBINATION OF THERAPIES FOR HEMO DISEASES WITH ANTI-CD38 ANTIBODIES AND SURVIVINE INHIBITORS
MX2016004573A (en) Nsp4 inhibitors and methods of use.
BR112017010627A2 (en) fused bicyclic compounds for treating diseases
EA202092450A2 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT

Legal Events

Date Code Title Description
FB Suspension of granting procedure